Bioavailability of Variably Aged MK-0974 Tablets (MK-0974-038)(COMPLETED)
Phase 1
Completed
- Conditions
- Migraine
- Interventions
- Registration Number
- NCT01209741
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Brief Summary
This study will evaluate the comparative bioavailability of three capsule formulations of MK-0974.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
- Subject is in good health
- Subject is a nonsmoker
- Subject is willing to comply with the study restrictions
Exclusion Criteria
- Subject has a history of stroke, chronic seizures, or major neurological disorder
- Subject has a history of cancer
- Subject is a nursing mother
- Subject has or has a history of any illness that might make participation in the study unsafe or confound the results of the study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 1 telcagepant potassium MK-0974 12MoRT 2 MK-0974 5Mo5C MK-0974 5Mo5C 3 MK-0974 12Mo5C MK-0974 12Mo5C
- Primary Outcome Measures
Name Time Method Area under the curve (AUC(0 to infinity) following single dose administration of MK-0974 12Mo5C and 5Mo5C formulations Through 48 hours postdose Peak plasma concentration (Cmax) following single dose administration of MK-0974 12Mo5C and 5Mo5C formulations Through 48 hours postdose
- Secondary Outcome Measures
Name Time Method Area under the curve (AUC(0 to infinity) following single dose administration of MK-0974 12MoRT and 5Mo5C formulations Through 48 hours postdose Peak plasma concentration (Cmax) following single dose administration of MK-0974 12MoRT and 5Mo5C formulations Through 48 hours postdose
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the mechanism of action of telcagepant potassium in migraine treatment?
How does MK-0974 compare to other CGRP antagonists in clinical trials for migraines?
Are there specific biomarkers that correlate with MK-0974 efficacy in migraine patients?
What are the long-term safety concerns associated with telcagepant potassium formulations?
What is the current status of gepant drugs in the migraine therapeutic landscape post-NCT01209741?